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Abstract
Background: The aim of  the present study was to determine whether the interleukin-6 (IL-6) -572G/C polymorphism cor-
relates with prostate cancer.
Methods: According to inclusion and exclusion criteria, the association of  the IL-6 -572G/C polymorphism with prostate 
cancer was searched in databases and analyzed using comprehensive meta-analysis software. Odds ratios (ORs) with 95% confi-
dence intervals (CIs) were used to assess the strength of  the associations.
Results: We considered a total of  six case-control studies including  2237 patients and 1754 controls and the meta-analysis 
results showed significant association between the IL-6 -572G/C polymorphism and prostate cancer risk(CC vs GG: OR = 
0.49, 95% CI =0.37-0.65;CG vs GG: OR =0.71, 95% CI = 0.58-0.87; the dominant model: OR =0.65, 95% CI = 0.54-0.79;the 
recessive model: OR =0.70, 95% CI = 0.58-0.85). In stratified analyses by ethnicity, significant associations were found among 
Asian populations. However, no significant association was found in Caucasian populations.
Conclusion: Our findings demonstrated that the -572G/C polymorphism of  the IL-6 gene may be a risk factor for the devel-
opment of  prostate cancer in Asians.
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Prostate cancer is a  common cause of  cancer-related 
death and is one of  the most commonly diagnosed malig-
nancies in men1. Recently numerous medical studies have 
made significant progress in the field. Age, family history, 
and race are the most consistently observed risk factors 
associated with prostate cancer. Especially age and inher-
ited factors are estimated to be responsible for 5% to 9% 
percentage of  this disease2. Recently,  molecular biolog-
ical and epidemiological studies results suggest that the 
pathogenesis of  prostate cancer may be associated with 
single nucleotide polymorphisms (SNPs) among several 
genes3-4.
Interleukin-6(IL-6) is a pleiotropic cytokine that not only 
exhibits immunological effect but also functions in hae-
matopoiesis, bone metabolism, and tissue regeneration5. 
In addition,IL-6 is widely believed to play a key role in 
the pathogenesis of  many cancers6. Located on chromo-
some 7p21,the IL-6 gene is composed of  five exons, four 
introns and a promoter region7. Many  studies have fo-
cused on the promoter region of  the IL-6 gene for many 
polymorphisms are identified in this region. Functional 
polymorphism(−572G/C,rs1800796) in the promoter 
region is associated with increased plasma levels of  IL-
6, which has been reported to influence IL-6 levels8. A 
previous  meta-analysis suggested that the IL6-174G/C 
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polymorphism is associated with an increased risk of  
prostate cancer9.
Several studies have been performed to figure out wheth-
er there is an association between prostate cancer and the 
IL-6 −572G/C polymorphism, but the results are equiv-
ocal. Meta-analysis combines the results from relevant 
studies, explores the heterogeneity and identifies sub-
groups associated with the factor of  interest.Therefore, 
we performed this meta-analysis to clarify the association 
of  this variant with prostate cancer.
Methods
Literature search and selection criteria
PubMed, Embase, Web of  Science, Google Scholar, Chi-
na Biological Medicine Database (CBMD), and the China 
National Knowledge Infrastructure (CNKI) databases 
were searched for  papers linking the IL6 −572G/C poly-
morphism prior to  March 2017, using the keyword: “in-
terleukin 6/IL6”,“−572G/C”,,“prostate cancer”,“poly-
morphism”. The search was not limited to English 
language articles. Furthermore, the reference lists of  re-
trieved articles were manually screened to obtain relevant 
papers.
Criteria for inclusion and exclusion
Studies included in this meta-analysis meet the following 
inclusion criteria: I) case-control design; II) evaluation of  
the correlation of  IL-6 −572G/C polymorphism with 
prostate cancer risk; and III)  adequate data to calculate 
the odds ratio (OR) and its corresponding 95% confi-
dence interval (CI). Of  studies published, the same case 
series, we selected the most recent papers. In addition, 
studies without effective information were excluded after 
the efforts to extract data from the included paper.
Data extraction
The following information was extracted: a) authors, b) 
year of  publication, c) country, d) ethnicity of  the study 
subjects, e) sample size, f) allele and genotype distribu-
tion, and g) evidence of  Hardy-Weinberg equilibrium 
(HWE) in the control population.
Statistical analysis
Meta-analysis was performed using a comprehensive me-
ta-analysis software program (BiostatCorporation,NJ, 
USA).The pooled OR and 95% CI were used to investi-
gate the association between the risk of  prostate cancer 
and IL-6 −572G/C polymorphism. In the present me-
ta-analysis, we adopted the following genetic models:a 
homozygote comparison(CC vs GG), a heterozygote 
comparison(CG vs GG),a dominant model(CC+CG vs 
GG) and a recessive model (CC vs CG+GG)10.  The vari-
ation caused by heterogeneity was estimated by calculat-
ing the inconsistency index I2, the random effects model 
was used to calculate the OR and 95% CI when I2>50%. 
Otherwise, the fixed effect model was applied. Publica-
tion bias was evaluated by Egger’s regression. A P value 
less than 0.05 was considered statistically significant.
Results
Study characteristics
The search strategy retrieved 21 relevant papers. Based 
on the inclusion criteria, 6 case-control studies met in-
clusive criteria 11-16, and 15 studies were excluded. The 
flow chart for the study selection is shown  in Figure 1. 
These 6 papers selected included 2237 cases and 1754 
healthy controls. The HWE test was performed on geno-
type distribution of  the controls, all included studies were 
in HWE (P>0.05) except Bao et al.The baseline charac-
teristics of  included studies are summarized in Table 1.
 
 
Figure 1. Study selection and inclusion process. 
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Country Ethnicity Cases/Controls -572G/C (Case/control) HWE 
test 
        CC          CG         GG       
Sun et al 2004 Sweden Caucasian 1337/753 2/4         109/74         1226/675 0.21 
Bao et al 2008 China Asian 136/120 50/65       39/27         47/28 0.00 
Wang et al 2009 USA Caucasian 116/109 1/0         19/25          233/225 0.41 
Lu et al 2011 China Asian 200/279 97/150       60/100        43/29 0.05 
Chen et al 2015 China Asian 212/237 79/110       96/102        37/25 0.85 
Huang et al 2016 China Asian 236/256 117/144      88/89         31/23 0.09 
HWE, Hardy-Weinberg equilibrium 
Meta-analysis results
The combined data showed that the IL-6 −572G/C poly-
morphism is associated with increased prostate cancer 
risk in various genetic models indicated in Table 2 (CC 
vs GG: OR = 0.49, 95% CI =0.37-0.65,Figure 2; CG vs 
GG: OR =0.71, 95% CI = 0.58-0.87; the dominant mod-
el: OR =0.65, 95% CI = 0.54-0.79; the recessive model: 
OR =0.70, 95% CI = 0.58-0.85). When stratified accord-
ing to ethnicity, we detected a significant association in 
Asians, but not in Caucasians.
Table 2 Summary ORs and 95%CI of Interleukin-6 
gene -572G/C polymorphism with prostate cancer risk. 
 
Variables N a CC vs GG CG vs GG Dominant model Recessive model 
    OR(95%CI)     Model OR(95%CI)    Model OR(95%CI)   Model OR(95%CI)   Model 
Total 6 0.49(0.37-0.65)     F 0.71(0.58-0.87)    F 0.65(0.54-0.79)   F 0.70(0.58-0.85)   F 
Ethnicity           
Asian 4 0.49(0.37-0.65)     F 0.62(0.45-0.83)    F 0.54(0.41-0.71)    F 0.71(0.58-0.86)   F 
Caucasian 2 0.46(0.10-2.07)     F 0.80(0.60-1.05)    F 0.78(0.60-1.03)    F 0.47(0.11-2.12)   F 
HWE           
yes 5 0.50(0.36-0.68)     F 0.69(0.56-0.86)    F 0.66(0.54-0.81)    F 0.75(0.61-0.92)   F 
no 1 0.46(0.25-0.83)     / 0.86(0.44-1.70)     / 0.58(0.33-1.00)     / 0.49(0.30-0.81)    / 
a Number of comparisons.   
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When patients were stratified according to HWE, a sig-
nificant association was found in the studies consistent 
with HWE. Sensitivity analysis was performed via assess 
 
Figure 2.Meta-analysis of the relationship between the IL-6 −572G/C  
polymorphism and prostate cancer risk(CC vs GG). 
the influence of  each individual paper on the pooled OR 
via deleting one single study each time.There is no single 
article that influenced the pooled ORs, suggesting that 
the results are stable(Figure 3).
 
Figure 3.Sensitivity analysis of the IL-6 −572G/C polymorphism with prostate cancer risk. 
Publication bias
The funnel plot was performed to assess the publication 
bias. There was no evidence of  publication bias visually 
from the funnel plot (Figure 4), which showed that the 
publication bias of  our meta-analysis was low.
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Figure 4. Egger’s funnel plot test. 
Discussion
Prostate cancer is the second most common cancer diag-
nosed in men, and the fourth most common cancer di-
agnosed worldwide. Although genetic variants appear to 
play an important role in prostate cancer risk, the precise 
mechanism is likely to be complex11. Recombinant ade-
novirus-p53 (rAd-p53) (Gendicine) is a newly developed 
medicine of  gene therapy that relies on the function of  
wild-type P53, which is safe and could prolong the sur-
vival time of  the patients with hepatocellular carcinoma 
and nasopharyngeal carcinoma12,13. There have been no 
reports regarding prostate cancer to date. As a multifacto-
rial cytokine, it is generally accepted that IL-6 plays a sig-
nificant role in the pathogenesis of  many forms of  can-
cer6. Several studies have shown an association between 
the IL-6 gene −572G/C polymorphism and the risk of  
prostate cancer, but the results are inconclusive. In order 
to provide comprehensive and reliable conclusions, we 
performed the present meta-analysis comprising six  in-
dependent case-control studies, including 2237 cases and 
1754 controls.
From the combined meta-analysis results, the data sug-
gest sthat −572G/C polymorphism was associated with 
the risk of  prostate cancer. For the difference in the en-
vironment in which they lived in, we perform a ethnici-
ty-specific subgroup analysis, and significant association 
was found in Asians, but not in Caucasians. Deviation 
of  allelic distributions from HWE may contribute to 
between-study heterogeneity, the sub-group analysis via 
limiting this meta-analysis to those papers that are con-
sistent with HWE revealed that our data was robust. No 
evidence showed publication bias in this meta-analysis.
The meta-analysis suggested that the GG genotype of  
IL-6 −572G/C polymorphism might be related to the 
increased risk of  prostate cancer in Asians. Neverthe-
less, the mechanism of  how this polymorphism relates to 
prostate cancer risk remains  unclear. Previous study sug-
gested that the GG and GC genotypes of  the −572G/C 
polymorphism are associated with higher IL-6 serum lev-
els than in the CC genotype14. An elevated serum IL-6 
level has been correlated with prostate cancer risk15. In 
addition, it is common to find discordant results between 
Asians and Caucasians with respect to gene polymor-
phisms, partly owing to a possible role of  ethnic differ-
ences in genetic backgrounds and the environment in 
which they lived16.
Although our study provides a better understanding of  
the IL-6 −572G/C polymorphism and susceptibility to 
prostate cancer, it has limitations. Firstly, only two studies 
involving Caucasian patients met inclusion criteria. This 
may not provide enough statistical power to detect the 
possible effects of  the −572G/C polymorphism in Cau-
casian patients. Secondly, original individual data could 
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not be extracted from each study and our results were 
based on unadjusted estimates, the introduction of  het-
erogeneity is therefore unavoidable and may affect our 
results. Thirdly, the possibility of  gene-gene interactions 
and environmental factors were also not considered in 
our study.
In summary, the present meta-analysis indicated that the 
IL-6 −572G/C polymorphism might increase the pros-
tate cancer risk in the Asian population.
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